Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Buy
51
THRD Quote, Financials, Valuation and Earnings
Last price:
$5.15
Seasonality move
:
17.27%
Day range:
$5.14 - $5.19
52-week range:
$3.18 - $16.94
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.81x
Volume:
323.6K
Avg. volume:
879.2K
1-year change:
-52.45%
Market cap:
$232.3M
Revenue:
--
EPS (TTM):
-$1.08
Analysts' Opinion
-
Consensus RatingThird Harmonic Bio has received a consensus rating of Hold. The company's average rating is a Hold based on 1 Buy rating, 3 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $4.58, Third Harmonic Bio has an estimated downside of -11.13% from its current price of $5.15.
-
Price Target UpsideAccording to analysts, the highest upside price target is $5.50 representing -100% upside increase from its current price of $5.15.
Fair Value
-
According to the consensus of 4 analysts, Third Harmonic Bio has -11.13% downside to fair value with a price target of $4.58 per share.
THRD vs. S&P 500
-
Over the past 5 trading days, Third Harmonic Bio has underperformed the S&P 500 by -2.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Third Harmonic Bio does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Third Harmonic Bio has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Third Harmonic Bio reported revenues of --.
Earnings Growth
-
Third Harmonic Bio has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Third Harmonic Bio reported earnings per share of -$0.29.
Enterprise value:
-52.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
1.53x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$37.7M | -$44M | -$58.9M | -$10.4M | -$16.4M | |
| EBITDA | -$37.7M | -$43.9M | -$58.8M | -$10.4M | -$16.4M | |
| Diluted EPS | -$1.61 | -$0.78 | -$1.08 | -$0.17 | -$0.29 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $129.2M | $292.8M | $272.4M | $290.5M | |
| Total Assets | -- | $129.2M | $298.7M | $277.7M | $294.6M | |
| Current Liabilities | -- | $5.7M | $5.7M | $5.4M | $7.1M | |
| Total Liabilities | -- | $175.9M | $9.6M | $8.6M | $9.5M | |
| Total Equity | -- | -$46.7M | $289.1M | $269.1M | $285.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$34.9M | -$20.4M | -$34.5M | -$5.6M | -$11.2M | |
| Cash From Investing | -$36K | -$169K | -$10K | -$1K | -$10K | |
| Cash From Financing | $196M | $799K | $50.5M | $798K | $210K | |
| Free Cash Flow | -$34.9M | -$20.4M | -$34.5M | -$5.6M | -$11.2M | |
THRD
Sector
Market Cap
$232.3M
$34.4M
Price % of 52-Week High
30.4%
44.25%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.82%
1-Year Price Total Return
-52.45%
-39.44%
Beta (5-Year)
--
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$5.15
200-day SMA
Sell
Level
$9.44
Bollinger Bands (100)
Sell
Level
2.97 - 9.39
Chaikin Money Flow
Sell
Level
-13.6M
20-day SMA
Buy
Level
$4.32
Relative Strength Index (RSI14)
Buy
Level
79.26
ADX Line
Buy
Level
46.14
Williams %R
Sell
Level
-2.7322
50-day SMA
Buy
Level
$3.83
MACD (12, 26)
Buy
Level
0.40
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Neutral
Level
5.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company’s product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
Stock Forecast FAQ
In the current month, THRD has received 1 Buy ratings 3 Hold ratings, and 0 Sell ratings. The THRD average analyst price target in the past 3 months is $4.58.
-
Where Will Third Harmonic Bio Stock Be In 1 Year?
According to analysts, the consensus estimate is that Third Harmonic Bio share price will drop to $4.58 per share over the next 12 months.
-
What Do Analysts Say About Third Harmonic Bio?
Analysts are divided on their view about Third Harmonic Bio share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Third Harmonic Bio is a Sell and believe this share price will rise from its current level to $3.00.
-
What Is Third Harmonic Bio's Price Target?
The price target for Third Harmonic Bio over the next 1-year time period is forecast to be $4.58 according to 4 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 3 analysts rate the stock a Hold.
-
Is THRD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Third Harmonic Bio is a Hold. 3 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of THRD?
You can purchase shares of Third Harmonic Bio via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Third Harmonic Bio shares.
-
What Is The Third Harmonic Bio Share Price Today?
Third Harmonic Bio was last trading at $5.15 per share. This represents the most recent stock quote for Third Harmonic Bio. Yesterday, Third Harmonic Bio closed at $5.15 per share.
-
How To Buy Third Harmonic Bio Stock Online?
In order to purchase Third Harmonic Bio stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Is it Too Late to Buy Gold?
Amid deep uncertainties about the future of the US economy,…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
54
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Sell
39
RGC alert for Apr 29
Regencell Bioscience Holdings [RGC] is down 11.18% over the past day.
Buy
76
EXOD alert for Apr 29
Exodus Movement [EXOD] is down 3.2% over the past day.
Sell
48
SBGSY alert for Apr 29
Schneider Electric SE [SBGSY] is down 0.17% over the past day.
